Cargando…

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis

Background: The pharmacokinetic/pharmacodynamics (PK/PD) target derived from the hollow-fiber system model for linezolid for treatment of the multidrug-resistant tuberculosis (MDR-TB) requires clinical validation. Therefore, this study aimed to develop a population PK model for linezolid when admini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Haoyue, He, Yuying, Davies Forsman, Lina, Paues, Jakob, Werngren, Jim, Niward, Katarina, Schön, Thomas, Bruchfeld, Judith, Alffenaar, Jan-Willem, Hu, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868619/ https://www.ncbi.nlm.nih.gov/pubmed/36699070 http://dx.doi.org/10.3389/fphar.2022.1032674

Ejemplares similares

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
por: Shao, Ge, et al.
Publicado: (2023)

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
por: Davies Forsman, Lina, et al.
Publicado: (2018)

Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China
por: Zheng, Xubin, et al.
Publicado: (2022)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
por: Ekqvist, David, et al.
Publicado: (2022)

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
por: Yuan, Yuan, et al.
Publicado: (2022)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
por: Azimi, Taher, et al.
Publicado: (2022)

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Evaluation of the impact of rifampicin on the plasma concentration of linezolid in tuberculosis co-infected patients
por: Yan, Pan, et al.
Publicado: (2023)

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
por: Millard, James, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China
por: Zou, Jin, et al.
Publicado: (2022)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

The Inhibition Effect of Linezolid With Reyanning Mixture on MRSA and its Biofilm is More Significant than That of Linezolid Alone
por: Zhang, Lulu, et al.
Publicado: (2022)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Barriers to Optimal Tuberculosis Treatment Services at Community Health Centers: A Qualitative Study From a High Prevalent Tuberculosis Country
por: Pradipta, Ivan S., et al.
Publicado: (2022)

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies
por: Garcia-Prats, Anthony J., et al.
Publicado: (2019)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study
por: Zheng, Xubin, et al.
Publicado: (2023)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Linezolid and Its Immunomodulatory Effect: In Vitro and In Vivo Evidence
por: Wang, Jin, et al.
Publicado: (2019)

Editorial: Pharmacology of infectious diseases: world tuberculosis day 2022
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Mycobacterium tuberculosis Beijing Type Mutation Frequency
por: Werngren, Jim
Publicado: (2013)

Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients
por: Märtson, Anne-Grete, et al.
Publicado: (2020)

Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients
por: Requena-Méndez, Ana, et al.
Publicado: (2014)

Model Based Identification of Linezolid Exposure–toxicity Thresholds in Hospitalized Patients
por: Fang, Jie, et al.
Publicado: (2021)

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex
por: Economou Lundeberg, Elin, et al.
Publicado: (2023)

A Review of Population Pharmacokinetic Analyses of Linezolid
por: Bandín-Vilar, Enrique, et al.
Publicado: (2022)

Linezolid Toxicity and Mitochondrial Susceptibility: A Novel Neurological Complication in a Lebanese Patient
por: Abou Hassan, Ossama K., et al.
Publicado: (2016)

Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis
por: Li, Yuan, et al.
Publicado: (2019)

Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018
por: McDowell, Ashley, et al.
Publicado: (2020)

Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report
por: Lee, Jaemin, et al.
Publicado: (2021)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Intrathecal/Intraventricular Linezolid in Multidrug-Resistant Enterococcus faecalis Ventriculitis
por: Lich, Brian F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qrtc4vlp7s768d90tlvc09j435